BioMed X – Seeding Biomedical Innovations BFM 91

BIOMED X

SEEDING BIOMEDICAL INNOVATIONS

BIOMED X

COMBINING THE BEST OF TWO WORLDS – ACADEMIA AND INDUSTRY – BIOMED X AIMS TO FOSTER BREAKTHROUGH MEDICAL INNOVATION WITH A MAJOR IMPACT ON SOCIETY.

SEEDING BIOMEDICAL INNOVATIONS PROJECT MANAGED BY: HAYDEN TURNER

BioMed X is an independent research institute located within the campus environment of the University of Heidelberg in Germany. Operating at the interface between academia and industry, the institute undertakes biomedical preclinical research projects in the fields of biomedicine, molecular biology, cell biology and diagnostics. All its research projects are sponsored by renowned partners and conducted by earlycareer scientists recruited from all over the world.

M

anaging Director Dr Christian Tidona, who started the company in 2013, explains the institute’s core principles: “BioMed X is based on a completely new innovation model which bridges the gap between academic research and the pharma industry. The model is unique, and is the culmination of my passion and experience from the past 20 years.”

He jokingly adds that he has two hearts in his chest, those of a scientist and of an entrepreneur. While doing his PhD in Heidelberg in the later 1990s, he started his first company. Now the owner of BioMed X, he is proud to say that unlike most start-ups, the company was founded with no investors, no public money and no exit strategy.

BioMed X Management Team (from left to right): Dr. Thomas Rückle, Senior Vice President Research; Dr. Christian Tidona, Founder & Managing Director & Yvonne Stappenbeck, Vice President HR & Operations.

2 | HEALTHCARE, HOTEL & LEISURE

BIOMED X

WRITING THE FUTURE At Twist Bioscience, we enable your research by providing the highest quality DNA, at the scale you need, to achieve your next discovery.

WE MAKE DNA FOR TEAMS THAT...

INNOVATE waste-reducing chemical processes DEVELOP personalized diagnostics for early detection SECURE safe and robust food supplies for all DESIGN novel biological therapeutics PRESERVE DNA for future generations

YOUR PARTNER IN DISCOVERY TWISTBIOSCIENCE.COM

TWIST BIOSCIENCE SYNTHETIC DNA IS THE CORE OF THE BIOTECHNOLOGY INDUSTRY To accelerate innovation in biotechnology, researchers need access to highquality, accurate, and rapid DNA synthesis.

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company based in South San Francisco, California. We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

The platform’s core is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We are leveraging its unique technology to manufacture a broad range of synthetic DNA-based products for customers specializing in synthetic biology, nextgeneration sequencing (NGS), and biologic drug discovery.

SYNTHETIC DNA FOR SYNTHETIC BIOLOGISTS High-quality DNA is an essential tool in the synthetic biologist’s toolbox.

Researchers are translating humanity’s ever-increasing knowledge of genomics to the design and testing of genetic parts. Such parts can then be assembled into protein-coding genes, genetic control elements, protein screening libraries, and many other configurations that service an array of applications.

Because our customers design their DNA in silico, and we construct it synthetically, novel sequences are as easily created as those that are naturally occurring. Our platform grants synthetic biology experts access to low-cost, high throughput DNA synthesis so they can test a broader range of genetic parts faster for a streamlined path to scientific answers, innovations and advancements that help engineer a better world.

SYNTHETIC DNA FOR NGS EXPERTS Historically, genomic analyses have been time-consuming and expensive to undertake. A targeted solution has been developed that allows scientists to extract only the parts of the genome they need for their experiments.

“Target capture” sequencing uses DNA probes that bind to genomic regions of interest in a given sample. Researchers can then run multiple samples on a single NGS run, saving both time and money.

Importantly, effective target capture success relies on high-quality probe synthesis. Our silicon DNA synthesis platform writes DNA with marketleading throughput, error rate, and uniformity. We write millions of NGS probes at once, delivering both premade and custom probe panels ready for high-quality target capture. We also provide reagents and workflows that help genomics experts further optimize their sequencing experiments.

SYNTHETIC DNA FOR BIOLOGIC DRUG DEVELOPERS Biologic drug discovery involves the screening of billions of candidate proteins against a target to identify molecules that may exhibit a desired therapeutic effect. The vast protein libraries used by drug developers start as libraries of synthetic DNA variants. Our DNA synthesis throughput means that, for the first time, every variant design in a DNA library can be synthesized directly for increased screening confidence and hit likelihood.

Twist Biopharma, a division of Twist Bioscience, leverages this library technology to generate superior biologics that precisely match the sequences found in the human body. Twist Biopharma partners with industry-leading pharmaceutical companies, providing an integral and unbiased resource for biologic therapeutic discovery and optimization.

Looking to accelerate your biotechnology innovation?

Learn more at www.twistbioscience.com Get in touch at sales@twistbioscience.com

BUSINESSFOCUSMAGAZINE.COM

BIOMED X

“BioMed X is a long-term project. I have no intention of ever selling the business, I want to create something that will have an impact in 50 or maybe 100 years, something that grows for the benefit of society.”

“I WANT TO CREATE SOMETHING THAT WILL HAVE AN IMPACT IN 50 OR MAYBE 100 YEARS, SOMETHING THAT GROWS FOR THE BENEFIT OF SOCIETY.” THE BRIGHTEST MINDS

How does the model work?

It all starts with selecting a major challenge within human disease biology as identified by researchers and pharma companies, one that has yet to be resolved. BioMed X then posts this challenge to the best universities and research institutions worldwide and invites young academic scientists to apply by submitting original project proposals to resolve the issue.

“We usually get about 150200 project proposals, from which we select the 15 brightest individuals. We fly them to Heidelberg for a five-day boot camp, where they are formed into 5 competing groups to convert the academic ideas into what we call ‘truly brilliant’ projects. Crucially, these are not only experimental but also implementable approaches.”

The winning team then enters the next phase - local incubation.

The winners, including their families, are moved to Heidelberg to live and work in the institute on the university campus for up to 5 years. During this period, the team receives very intense mentoring from industry (the pharma sponsor), academia (the

HEALTHCARE, HOTEL & LEISURE | 5

BIOMED X

local ecosystem) and BioMed X (head of research). At the end of the five-year project, the pharma partner receives the rights to apply the validated research results.

Selecting a handful of lucky winners from such a large pool of experts can’t be easy, but BioMed X applies a structured selection process. “The key criterion is originality and quality of the science. We want outstanding scientists who come up with very elegant experimental approaches, that would stimulate thinking outside the box,” says Dr Tidona.

“We get a very diverse set of backgrounds from molecular biology to mathematicians and electrical engineers, from any country and any nationality. It is very important for our model to have this outstanding crosspollination of outstanding scientists looking at the problem from completely different perspectives. This is the secret of innovation.”

in autoimmune diseases. The team is seeking to develop a new platform technology that leads to the identification of antigens recognized by T-cells involved in autoimmune responses.

And more recently, in June this year, BioMed X initiated its eighth joint research programme with Merck KGaA, Darmstadt, Germany. The new programme will explore the role of extrachromosomal DNA in cancer and will complement the research of two ongoing

oncology programmes at BioMed X in the fields of DNA damage response and RNA splicing.

One cannot avoid asking about the most-debated medical topic of today - Covid-19. Has this been a challenge that has been also addressed by BioMed X? Dr Tidona says: “Instead of focusing on the vaccines, we have started a worldwide effort to build a universal rapid antiviral response platform which will allow us

“YOU NEED THE CRITICAL MASS OF TALENT TO HAVE AN IMPACT IN INNOVATION”

SUCCESSFUL OUTCOME

As all the projects are unique, it is difficult to highlight one as an example. Dr Tidona mentions a research collaboration project with Roche Diagnostics in the field of nanomaterial-based biosensors for near-patient testing. BioMed X successfully achieved the proof of principle for a new sensor platform allowing the analysis of several different parameters from blood samples with one single device.

Following BioMed X’s strategy, the intellectual property (IP) and know-how have been transferred to Roche Diagnostics for further development.

Another difficult challenge has been addressed with Janssen, focused on rapid identification of autoantigens

6 | HEALTHCARE, HOTEL & LEISURE

BUSINESSFOCUSMAGAZINE.COM

BIOMED X

to discover, develop, test and mass-manufacture new drugs against any viral pathogen in less than six months. All this currently takes 15-20 years. We need technologies that are much faster, to be able to better handle future pandemics. This is something that we want to develop in the near future.”

GROWING TO SERVE

BioMed X Institute serves a large purpose in advancing translational medicine by leveraging synergies and fostering cross-pollination in biomedical preclinical research.

BUSINESSFOCUSMAGAZINE.COM

Given the outstanding results, Dr Tidona may be rightly proud of his company’s achievements.

“We started with a big promise - to bridge the gap between academic research and industry. For me, our greatest achievement is that of the 9 projects completed, 8 were acquired by respected pharma companies and have triggered a fully-fledged discovery programme. I’m very proud of this, as such a success rate in the field of innovation is quite rare.”

Given the company’s success, are there any challenges worth mentioning?

“The biggest challenge is

scaling the model up to other locations while maintaining the quality and the culture - a big success factor,” says Dr Tidona, who is now doing just that, building a similar hub in Israel, where the core values and culture are being instigated from scratch.

He emphasises that values and quality are more important than speed. “My desire is to create impact for human society. Talent is distributed evenly across the globe but the opportunity to develop that talent is not. With global mobility, we are now entering an age when every person of talent can choose where they want to pursue their goals.

This needs to be kept in mind when creating the innovation hubs. You need the critical mass of talent to have an impact in innovation.”

With the expansion plans on the agenda, it looks like Dr Tidona is going to be busy for the rest of his life. “Busy is not the right word. I’m going to have fun for the rest of my life,” he affirms.

HEALTHCARE, HOTEL & LEISURE | 7

BIOMED X

WWW.BIO.MX